Kornimate/medical-research-clean huggingface dataset:
evaluation of 68-ganota-anti-her2 vhh1 uptake in brain metastasis of cancer patients

Conditions: Carcinoma; Receptor, ErbB-2

Summary: this study investigates the uptake of the radiopharmaceutical 68-ganota-anti-her2 vhh1 in brain metastasis using pet/ct imaging. patients with her2-positive and her2-negative cancer will be included and the uptake in their lesions will be compared. optional 68-ganota-anti-her2 vhh1 scans may be performed during or after treatment, at time points 12±6 weeks and 24±9 weeks after the first scan.


Eligibility criteria:
inclusion criteria: * patients who have given informed consent * age 18 years or older * patients with brain metastasized cancer, with at least 1 brain lesion of at least 8 mm maximal diameter, as measured by ct or mri. * patients with potentially her2-positive cancer. either a her2 staining should have been done in standard of care, or sufficient tissue should be available for her2-staining for study purpose. exclusion criteria: * pregnant patients * breast feeding patients * patients with recent (\< 1 week) gastrointestinal disorders with diarrhea as major symptom * patients with any serious active infection * patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the test radiopharmaceutical * patients who cannot communicate reliably with the investigator * patients at increased risk of death from a pre-existing concurrent illness

Keywords: brain metastasis her2
treatment of aa amyloidosis

Conditions: AA Amyloidosis

Summary: the purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nl-saa1-01in a patient with aa amyloidosis.


Eligibility criteria:
inclusion criteria: * biopsy proven aa amyloidosis * measurable disease * ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records exclusion criteria: * participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures
traditional medicine use in low back pain

Conditions: Chronic Low Back Pain (CLBP)

Summary: chronic low back pain (clbp) is classified as one of the leading causes of disability worldwide. furthermore, the painful experience of clbp can be influenced by some already established factors, such as beliefs, self-efficacy, and kinesiophobia. beliefs are pre-established ideas that can influence physical functionality, pain experience, social functioning, and adherence to clbp treatment clique ou toque aqui para inserir o texto. among them is traditional medicine, a practice carried out by some populations that continue to trust their own popular medicine to meet their health demands. according to the who, traditional medicine (mt) or popular medicine (mp) is a practice reproduced in different cultures and based on beliefs, the sum of experiences and knowledge, whose objective is to prevent, treat or cure illnesses, whether physical or mental. this habit includes the use of home remedies, which are based on the manipulation of plant, animal, and mineral extracts for therapeutic purposes. furthermore, it is important to point out that, as it is a chronic condition, individuals living with clbp are strongly influenced by psychological factors, such as kinesiophobia (avoidance of exercise), catastrophizing (intensifying fear of movement, as they feel that pain is a threat), and low self-efficacy in processing and modulating pain, increasing levels of pain and disability. also, in addition to this, socioeconomic level is one of the determinants of the incidence and intensity of chronic pain. in short, although the practice of tm has been recognized for decades, it is not known whether there is a relationship between this belief and the levels of self-efficacy, kinesiophobia and catastrophizing of individuals with clbp in northern brazil. therefore, this study aims to identify the use of tm and its impacts on the functional activities and quality of life of individuals with clbp in the northern region of brazil. this is a cross-sectional observational study. individuals participating in this research will be invited to respond online to the questionnaire prepared by the authors of this study. continuous data will be analyzed descriptively using mean and standard deviation; categorical data will be described in frequency form, and the normality of the data will be analyzed to identify the possibility of using parametric or non-parametric statistical tests.


Eligibility criteria:
inclusion criteria: * individuals over 18 years of age * both genders * diagnosed with chronic low back pain * who have had pain for at least three months * who are natives of the northern region of brazil exclusion criteria: * individuals with low back pain of oncological origin * recent traumas that may have caused the pain (such as falls, car accidents, and fractures) * patients in the postoperative period * bedridden patients.

Keywords: traditional medicine beliefs lower back pain.
virtual reality to teach, improve outcomes, and engage (virtue): virtual reality to improve gluten-free diet knowledge in pediatric celiac disease

Conditions: Celiac Disease in Children

Summary: 1. specific aim (1) is to assess both the immediate and longer term impact of virtue on the patient's gfd knowledge compared to standard of care (soc) dietary education. 2. specific aim (2) is to determine the impact of virtue on patient qol, symptomatology, and celiac biomarkers (tissue transglutaminase antibodies, deamidated gliadin peptide iga, deamidated gliadin peptide igg, and total serum iga).

the global burden of celiac disease (cd) is estimated to be 1% in western countries and 0.7-1.4% of the global population.the only treatment for cd is a strict, lifelong gluten free diet (gfd). however, dietary adherence is the main barrier against disease control. whereas experiential learning, learning through experience, has been associated with greater impact in achieving desired nutritional outcomes in pediatric populations. replicating the environments in which patients would make food choices in clinic is not feasible. previous research, in addition to preliminary results indicate that virtual reality (vr) may act as an effective precursor to the real world by providing a safe and immersive learning environment. as such, the investigators seek to investigate how vr use to teach, improve outcomes, and engage (virtue) will affect patient gfd knowledge, qol, symptoms, and cd biomarkers. the central hypothesis will tested through the following specific aims: 1. specific aim (1) is to assess the immediate and long-term impact of virtue on children's gfd knowledge compared to soc education. the investigators hypothesize that virtue with soc education, will improve children's gfd knowledge by 10-20%, opposed to soc alone 2. specific aim (2) is to determine the impact of virtue on patient qol. the investigators hypothesize that virtue with soc education, will improve children's qol scores, opposed to soc alone. 3. specific aim (3) is to determine the impact of virtue on decline of cd biomarkers (tissue transglutaminase antibodies and deamidated gliadin peptide igg). the investigators hypothesize that virtue with soc education, will reduce levels of cd biomarkers faster, compared to soc alone.

Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis of cd per american or european guidelines * ages 8-18 years of all genders exclusion criteria: -significant developmental delays
pilot study of the effect of duavee® on benign breast tissue proliferation

Conditions: Breast Cancer

Summary: the purpose of this study is to learn whether daily use of duavee® is accepted and tolerated by peri- and post-menopausal women at moderate risk for development of breast cancer.

duavee® is tissue specific estrogen complex of bazedoxifene plus conjugated estrogen which is fda approved for relief of menopausal symptoms and prevention of osteoporosis in women with a uterus who have not been diagnosed with estrogen dependent neoplasia. the overall purpose of this research is to demonstrate in a preliminary fashion that despite reduction in menopausal symptoms, (duavee®) does not increase and may decrease proliferation in benign breast tissue in a cohort of peri- or post-menopausal women at moderately increased risk for breast cancer. if this pilot shows rapid accrual, good retention, and lack of significant increase in the risk biomarker ki-67 in benign breast tissue, a larger prevention trial is envisioned

Eligibility criteria:
inclusion criteria: * women with vasomotor symptoms with a uterus who are postmenopausal or in late menopause transition * body mass index (bmi) \<36 kg/m2 * class i-iii mammogram within 6 months of random periareolar fine needle aspiration (rpfna); if class 0 or 4, must be resolved with additional procedures * if previously on oral contraceptives or hormone replacement, off for 8 weeks or more prior to baseline rpfna; the exception is low dose vaginal hormones * confirmed moderate risk of developing breast cancer * rpfna results within study defined range * kidney and liver function within study defined range * willing and able to comply with study related procedures exclusion criteria: * previous biopsy showing evidence of breast cancer * have a predisposition to or prior history of thromboembolism, deep venous thrombosis, pulmonary embolism, or stroke * history of renal or liver disease * prior ovarian or endometrial cancer * stopped or started hormone replacement within 8 weeks * any other condition or intercurrent illness that in the opinion of the investigator makes the woman a poor candidate for rpfna * currently taking or have taken specific medications in the past 6 months * participation on any chemoprevention trial within 6 months * current illness which would make potential participant unsuitable for enrollment
pattern of dyslipidemia among patients with acute coronary syndrome at sohag university hospital

Conditions: Acute Coronary Syndrome

Summary: in this study, i am aime to analyze lipid profile in patients with acs who presents at sohag university hospital, and its clinical and complications pattern.

coronary artery disease (cad) is the most important cause of death in men and women the great majority of acs patients have at least one major risk factor. acute coronary syndrome (acs) is a major reason for coronary care unit ( ccu )sohag university hospital admission the risk of cad was about 4 and 3 times higher in male and female smokers than nonsmokers respectively (baba s et. al ; 2006) dyslipidemia has been identified as one of most important modifiable risk factor for cad . treating dyslipidemia has clear benefits in the primary and secondary prevention of coronary heart disease (chd) in both sexes . this study focused on dyslipidemia as a risk factor of acute coronary syndrome (acs).

Eligibility criteria:
inclusion criteria:: clinical diagnosed acute coronary syndromes - exclusion criteria: * chronic coronary syndrome
identification and clinical relevance of an oxytocin deficient state (melatonin study)

Conditions: Oxytocin Deficiency; Hypopituitarism; Hypothalamic Obesity; Pituitary Dysfunction; Central Diabetes Insipidus; Social Isolation

Summary: oxytocin (ot) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. ot plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. a few studies suggest the existence of a possible ot deficient state in hypopituitarism. in animal models, melatonin has shown to increase ot release. this study is designed to evaluate oxytocin values after administration of melatonin in adults (healthy volunteers and patients with hypopituitarism). the investigators hypothesize that ot response will be blunted following melatonin in patients with hypopituitarism compared to healthy controls.


Eligibility criteria:
inclusion criteria: * patients with hypopituitarism (hypo) (\>1 pituitary hormone deficiency) and stable hormone replacement for the prior three months * at least one clinical sign of hypothalamic damage exclusion criteria: * uncorrected hormone deficiency * creatinine \>1.5mg/dl * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \>2.5x upper limit of normal * hematocrit less than 30% * suicidality or active psychosis * participation in a trial with investigational drugs within 30 days * using a high glucocorticoid dose * vigorous physical exercise * alcohol intake within 24 hours before the study participation * evidence of any acute illness or any illness that the investigator determines could interfere with study participation or safety * pregnancy or breastfeeding for last 8 weeks * known allergies towards melatonin * patients refusing or unable to give written informed consent * patients receiving fluvoxamine and/or impossibility to stop hypnotics 48 hours prior to the study visit. * additionally for healthy controls: the presence of brain or pituitary tumor, radiation involving the hypothalamus or pituitary, history of hypopituitarism or receiving testosterone or glucocorticoids esters.

Keywords: oxytocin melatonin hypopituitarism vasopresin deficiency
neuromodulation after spinal cord injury to improve limb function

Conditions: Spinal Cord Injury; Spinal Cord Injury Cervical

Summary: the university at buffalo (ub) department of rehabilitation sciences is looking for adult volunteers with and without spinal cord injuries for a study on hand movement. the goal of the study is to learn about how the brain, nerves, and muscles of the body are connected and perform everyday tasks. this may help us to develop ways to improve the hand functions of people with spinal cord injuries.

the main goal of rehabilitation strategies in humans with spinal cord injury (sci) is to strengthen transmission in spared neural networks to restore functional movements. recent evidence showed that neuromodulation approaches may increase the transmission in corticospinal pathway in humans with sci and improve functional outcomes. therefore, the investigators aim to investigate how the noninvasive brain stimulation protocols affects neuroplasticity of corticospinal pathway. specifically, the investigators will use the repetitive transcranial magnetic stimulation (rtms) to explore its effect. the investigators will investigate the effect of short-term and long-term rtms application in individuals with sci.

Eligibility criteria:
inclusion criteria: * healthy adults between the ages of 18-75 years old who are right-handed * adults between the ages of 18-75 years old who have had a spinal cord injury (sci) exclusion criteria: for both healthy individuals and those with sci: * uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease * any debilitating disease prior to the sci that caused exercise intolerance * ongoing major depression or altered cognitive status * metal plate in skull * history of seizures * receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs * pregnant females

Keywords: spinal cord injury sci stimulation paralysis rtms transcranial magnetic stimulation
a pilot study to treat patients with chronic hepatitis c virus (hcv) genotype 1 and end-stage renal disease (esrd)

Conditions: Chronic Hepatitis C; End Stage Renal Disease

Summary: 1. a maximally tolerated dose of ribavirin can be defined in each patient with esrd undergoing hemodialysis. 2. patients with chronic hepatitis c virus (hcv)and end-stage renal disease (esrd)undergoing hemodialysis will be able to tolerate and remain on treatment with peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir. 3. a significant percentage of patients with chronic hcv and esrd undergoing hemodialysis can achieve rapid virologic response (rvr), extended virologic response (ervr) and sustained virologic response (svr) when treated with peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir.

patients with esrd will be treated with a dose escalation of ribavirin starting from 200 mg everyday (qd) to a maximal tolerated dose. peginterferon will then be added. ribavirin will be dose adjusted as needed. boceprevir will then be added. ribavirin will be dose adjusted as needed. patients will be monitored for ervr and svr. the study end-point is ervr.

Eligibility criteria:
inclusion criteria: * chronic hcv defined by: * a history of a positive anti-hcv or hcv rna for \> 6 months or * a liver biopsy demonstrating at least portal fibrosis * hcv genotype 1 * no prior treatment with any interferon or peginterferon preparation * esrd undergoing hemodialysis for at least 6 months * willingness not to conceive a child during treatment and for 6 months following discontinuation of treatment. exclusion criteria: * histologic evidence of cirrhosis * any co-existent liver disease * a platelet count \< 90,000 * a total white blood cell (wbc) \< 2.5 * an absolute neutrophil count \< 1.5 * hemoglobin \< 11 gm/dl on epoetin-alpha * positive test for anti-hiv * pregnancy of the patient or their intimate partner * women who are breast feeding * significant cardiovascular disease * history of suicide intent, severe depression requiring hospitalization or significant psychiatric disease * malignancy within 5 years of enrollment except for squamous or basal cell skin cancer * co-existent immune disorder such as lupus, rheumatoid as arthritis, colitis, crohns disease, sarcoidosis, etc. * any patient in the opinion of the investigator who would not be a satisfactory study candidate

Keywords: chronic hepatitis c hcv end stage renal disease esrd boceprevir ribavirin peg-interferon triple therapy
oxygenation procedure for obese patients during intubation in the operating room

Conditions: Anesthesia Induction

Summary: obesity is a risk factor for difficult intubation, with an incidence of up to 15.5%, and difficult mask ventilation. obesity also reduces the functional residual capacity (frc) of the lungs, the main reservoir of oxygen during apnoea. complications associated with induction and intubation in the operating room are more frequent in obese patients. preoxygenation is a cornerstone in the management of patients at risk of desaturation during induction. the study aims to compare two oxygenation strategies , in obese patients. oxygenation using a combination of niv (non invasive ventilation) and hfno (high flow nasal oxygen) compared with niv alone in the operating room for induction of general anaesthesia with orotracheal intubation.


Eligibility criteria:
inclusion criteria: * patient requiring general anaesthesia with orotracheal intubation in the operating room * obese patient (body mass index , bmi ≥ 30kg/m2) * patient affiliated to or benefiting from a social security scheme * patient having signed the free and informed consent form. exclusion criteria: * haemodynamic instability * intubation without laryngoscopy (fibroscope intubation) or nasotracheal intubation * emergency surgery not allowing patient consent. * patient with a contraindication to niv or ohd * protected patients: adults under guardianship, curatorship or other legal protection; deprived of liberty by judicial or administrative decision; pregnant, breast-feeding or parturient women; hospitalised without consent.

Keywords: non invasive ventilation high flow nasal oxygen intubation obese
egg white for phosphorus control in haemodialysis patients

Conditions: Renal Insufficiency, Chronic; Dialysis; Hyperphosphatemia

Summary: to evaluate the effect on phosphatemia in hemodialysis patients of replacing the meat or fish included in two meals a week with an amount of egg white containing the same quantity of proteins.

hyperphosphatemia develops in the majority of patients with end-stage renal disease (esrd). it is responsible for severe complications such as mineral bone disease, and has a role in worsening the cardiovascular mortality of dialyzed patients. therefore, a close control of serum phosphorus remains a cornerstone in the clinical management of dialyzed patients to improve their long term prognosis. there are multiple sources of phosphorus in the diet that could be the target of such a dietary intervention but, because of important differences in bioavailability, they are not all equally relevant in influencing phosphatemia. among them animal proteins that have a bioavailability of about 60% represent an important target for phosphate-lowering nutritional interventions. however, lowering the protein content of the diet in hemodialysis (hd) patients may be dangerous because it may increase the the risk of malnutrition hence worsening their prognosis. in the present study we intend to explore an alternative strategy to lower the intake of phosphate with animal proteins by replacing the meat or fish included in two meals a week with egg white that is reach of proteins but has virtually no phosphate.

Eligibility criteria:
inclusion criteria: * thrice weekly 4 h standard bicarbonate hd treatment with an at least 6-month vintage * stable dialysis dose and modality at least by 3 months * hyperphosphataemia (serum phosphate ≥5.0 mg/dl) at least by 3 months * stable dietary intake at least by 3 months * stable body weight at least by 3 months * stable biochemical markers at least by 3 months exclusion criteria: * diabetes * liver disease * malignancy * previous parathyroidectomy * psychiatric diseases * non-collaborative patients

Keywords: hyperphosphatemia hemodialysis dietary treatment egg white protein energy wasting
interactive tablet compared to oral midazolam as premedication in preoperative anxiety in children

Conditions: Anxiety

Summary: preoperative anxiety is an undesirable outcome in pediatric surgical patients.it can lead to behavioral trouble such as enuresis, apathy and sleep disorders. to prevent this anxiety,many tools can be used for premedication like pharmacological:midazolam, clonidine, hydroxysine or non pharmacological tools such as parental presence,hypnosis and interactive tablet. the purpose of the study is to compare the effect of interactive tablet to oral midazolam.on preoperative anxiety in children prior to elective surgery

this study is a prospective,randomized, active treatment controlled trial.it enrolls 100 children . after written and informed consent,the study participants were randomly assigned using a computer generated table to one of two treatment groups prior to elective surgery. group t: will receive an interactive tablet containing many cartoon's videos 20 minutes before the parental separation and until the anesthesia induction group md:will receive oral midazolam 20 minutes before parental separation with 0.5 mg/kg (max 20mg) anxiety assessement was done using the modified yale perioperative anxiety scale( mypas) at the separation of parents,the admission in the operating room and the anesthesia induction. facial mask acceptance,post operative agitation (paeds score: pediatric anesthesia emergence of delirium) and parental satisfaction were also assessed.

Eligibility criteria:
inclusion criteria: * 3-10 years old children * elective surgery * asa ps i/ii exclusion criteria: * parental refusal * emergency procedure * behavioral or psychiatric disorders * allergy or hypersensitivity to midazolam